Novel dual inhibitor targeting CDC25 and HDAC for treating triple-negative breast cancer
Authors:
Preprint
- 24 July 2024
- preprint
- Published by Springer Nature in Research Square
Abstract
Triple-negative breast cancer (TNBC) poses a significant challenge for treatment due to its aggressive nature and the lack of effective therapies. This study developed dual inhibitors against cell division cycle 25 (CDC25) and histone deacetylases (HDACs) for TNBC treatment. CDC25 phosphatases are crucial for activating cyclin-dependent kinases (CDKs), the master regulators of cell cycle progression. HDACs regulate various biological processes by deacetylating histone and non-histone proteins, affecting gene expression, chromatin structure, cell differentiation, and proliferation. Dysregulations of HDACs and CDC25s are associated with several human malignancies. We generated a group of dual inhibitors for CDC25 and HDAC by combining the molecular structures of CDC25 (quinoline-5,8-dione) and HDAC (hydroxamic acid or benzamide) pharmacophores. The newly developed compounds were evaluated against solid-tumor, leukemia, and non-malignant breast epithelial cells. Among the synthesized compounds, 18A emerged as a potent inhibitor, demonstrating significant cytotoxicity against TNBC cells, superior to its effects on other cancer types while sparing non-malignant cells.18A possessed similar HDAC inhibitory activity as Entinostat and potently suppressed the CDC25 activity in cells. Additionally, 18A hindered the progression of S and G2/M phases, caused DNA damage, and induced apoptosis. These findings suggest that 18A holds promise as a targeted therapy for TNBC and warrants further preclinical development.Keywords
All Related Versions
- Version 1, 2024-07-24, Research Square
- Published version: Apoptosis, 29 (11-12), 2047.
This publication has 29 references indexed in Scilit:
- Hdac1-deficiency affects the cell cycle axis Cdc25-Cdk1 causing impaired G2/M phase progression and reduced cardiomyocyte proliferation in zebrafishBiochemical and Biophysical Research Communications, 2023
- Targeting histone deacetylases for cancer therapy: Trends and challengesActa Pharmaceutica Sinica B, 2023
- Cyclin-dependent kinases in breast cancer: expression pattern and therapeutic implicationsMedical Oncology, 2022
- Research progress of dual inhibitors targeting crosstalk between histone epigenetic modulators for cancer therapyEuropean Journal of Medicinal Chemistry, 2021
- Recent progress on HDAC inhibitors with dual targeting capabilities for cancer treatmentEuropean Journal of Medicinal Chemistry, 2020
- Medicinal chemistry insights into novel CDC25 inhibitorsEuropean Journal of Medicinal Chemistry, 2020
- Identification of highly potent and selective Cdc25 protein phosphatases inhibitors from miniaturization click-chemistry-based combinatorial librariesEuropean Journal of Medicinal Chemistry, 2019
- Discovery of novel 9H-purin derivatives as dual inhibitors of HDAC1 and CDK2Bioorganic & Medicinal Chemistry Letters, 2019
- Novel anti-inflammatory function of NSC95397 by the suppression of multiple kinasesBiochemical Pharmacology, 2014
- Histone deacetylase inhibitors and genomic instabilityCancer Letters, 2009